Description
ADCC-enhanced Conatumumab is a non-fucosylated anti-DR5 therapeutic biobetter antibody.
Antibody Indication
Colorectal cancers
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced DR5 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNFRSF10B
Full Name
TNFRSF10B Gene(Protein Coding)
TNF Receptor Superfamily Member 10b
Background
The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene. [provided by RefSeq, Mar 2009]
Alternative Names
Drozitumab;912628-39-8;PRO95780;anti-DR5;rhuMAb DR5;TNFRSF10B;tumor necrosis factor receptor superfamily, member 10b;tumor necrosis factor receptor superfamily member 10B;CD262;DR5;KILLER;TRAIL R2;TRICK2A;TRICKB;Fas-like protein;death receptor 5;cytotoxic
Gene ID
8795
UniProt ID
O14763
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with TNFRSF10B include Squamous Cell Carcinoma, Head And Neck and Glioblastoma Multiforme.
Related Pathways
Its related pathways are Apoptosis Modulation and Signaling and Signaling by GPCR.
Function
Cytotoxic ligand TNFSF10/TRAIL receptor (PubMed: 10549288). The adaptor molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signal complex (DISC) performs proteolytic activation of caspase-8, which in turn initiates a cascade of caspase (aspartate-specific cysteine protease) and mediates apoptosis. Promote the activation of nf-kpa-b. It is essential for apoptosis induced by endoplasmic reticulum stress.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Cell Death antibody; Signaling Transduction antibody
Post-translational modifications
1.Ubiquitination at Lys2452.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn156
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Conatumumab
Description
ADCC-enhanced Conatumumab is a non-fucosylated anti-DR5 therapeutic biobetter antibody.
Antibody Indication
Colorectal cancers
